Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.37 |
| ▸ | ESRRB | O95718 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESRRG | P62508 | 2/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156563 | 0.84 | — | — | |
| SCHEMBL17285998 | 0.81 | GBA1 (0.41) | GBA1ESRRGGLB1GUSB | |
| SCHEMBL17284479 | 0.79 | GBA1 (0.36) | GBA1GLB1GUSB | |
| SCHEMBL22878450 | 0.79 | GBA1 (0.36) | GBA1GLB1GUSB | |
| SCHEMBL4084136 | 0.76 | ALDH1A1 (0.44) | GBA1GLB1TSHRUSP2MEN1 | |
| SCHEMBL6569119 | 0.76 | ALDH1A1 (0.44) | GBA1GLB1TSHRUSP2MEN1 | |
| SCHEMBL13377081 | 0.75 | GLB1 (0.56) | GBA1GLB1GUSB | |
| SCHEMBL19636877 | 0.75 | GBA1 (0.37) | GBA1GLB1GUSBTSHRPYGL | |
| SCHEMBL14968077 | 0.75 | — | — | |
| SCHEMBL17282012 | 0.74 | GBA1 (0.37) | GBA1GLB1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-1960383-B1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-04-28 | — | — | EP | disclosed |
| EP-1960383-A1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7388095-B2 | 5-substituted indole-2-carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007063000-A1 | 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123525-A1 | 5-Substituted indole-2-carboxamide derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | GBA1 2271/4885ESRRB 2119/4885ESR1 1125/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GBA1 2271/4885ESRRB 2119/4885ESR1 1125/4885 |
| US-20070123525-A1 | 5-Substituted indole-2-carboxamide derivatives | HRH4, HRH3, HCAR2 | GBA1 2309/4885ESRRB 524/4885ESR1 1020/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GBA1 2271/4885ESRRB 2119/4885ESR1 1125/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GBA1 2271/4885ESRRB 2119/4885ESR1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.